Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 5, 1998, Pages 667-669

  Heinzlef, Olivier ^a,b   Lotz, Jean Pierre ^b   Roullet, Etienne ^a  

^a Department of Neurology ^*

^b HÔPITAL TENON   (France)

Author keywords

Adverse effect; Carboplatin; Severe neuropathy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; ETOPOSIDE; VINBLASTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG RESISTANCE; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; MALE; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; STEM CELL TRANSPLANTATION;

EID: 0031899544     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.5.667     Document Type: Article

References (11)

1. Lotz JP, André T, Donsimoni R, et al. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995;75:874-85.
2. Horwich MS, Cho L, Porro RS, et al. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 1977;2:7-19.
3. Patel SR, Forman AD, Benjamin RS. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 994;86:305-6
4. Siegal T, Haim N. Cisplatin induced peripheral neuropathy: frequent off-deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66:1117-23.
5. Mollman JE, Hogan MW, Glover DJ, et al. Unusual presentation of cis-platinium neuropathy. Neurology 1988;38:488-90.
6. Gerritsen van der Hoop R, van der Burg MEL, Ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;66:1697-702.
7. Anderson H, Wagstaff J, Crowther D, et al. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 1988;21:1471-9.
8. Adams M, Kerby IJ, Rocker I, et al on behalf of the Swons Gynaecological Cancer Group. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 1989;1:57-60.
9. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985;12(suppl A):125-36.
10. Broun RE, Sridhara R, Sledge GW, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995;13:2050-5.
11. Legha SS, Dimery IW. High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 1985;3:1373-8.